Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study
Objective. To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods. The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustai...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/7395506 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553607334985728 |
|---|---|
| author | Wencong Li Jing Liang Jihong An Lingdi Liu Yihui Hou Lu Li Wen Zhao Luyao Cui Ningning Xue Zaid Al-Dhamin Tao Han Yuemin Nan Liaoyun Zhang |
| author_facet | Wencong Li Jing Liang Jihong An Lingdi Liu Yihui Hou Lu Li Wen Zhao Luyao Cui Ningning Xue Zaid Al-Dhamin Tao Han Yuemin Nan Liaoyun Zhang |
| author_sort | Wencong Li |
| collection | DOAJ |
| description | Objective. To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods. The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. Results. Four genotypes and six subtypes were identified as follows: 1b (1187, 54.90%), 2a (790, 36.54%), 3a/b (134, 6.20%), 6a/n (44, 2.04%), mixed genotypes (2a-6a or 2a-3a) (7, 0.32%). Overall, 99.01% patients achieved SVR12, while 98.43% achieved SVR24. All patients treated with elbasvir/grazoprevir (EBR/GZR), sofosbuvir/velpatasvir ± ribavirin (SOF/VEL ± RBV), and SOF/ledipasvir (LDV) achieved SVR12 or SVR24; 92.86% SVR12 and 95.83% SVR24 were observed in patients using SOF + RBV. SVR12 was higher in noncirrhosis versus compensated cirrhosis patients (100% vs. 97.09%, p=0.022). No severe drug-related adverse event was observed. Conclusions. Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile. |
| format | Article |
| id | doaj-art-678c9d3f40fb4faebee1eb4cab7946d3 |
| institution | Kabale University |
| issn | 2291-2797 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-678c9d3f40fb4faebee1eb4cab7946d32025-02-03T05:53:39ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/7395506Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter StudyWencong Li0Jing Liang1Jihong An2Lingdi Liu3Yihui Hou4Lu Li5Wen Zhao6Luyao Cui7Ningning Xue8Zaid Al-Dhamin9Tao Han10Yuemin Nan11Liaoyun Zhang12Department of Traditional and Western Medical HepatologyDepartment of HepatologyDepartment of Infectious DiseasesDepartment of Traditional and Western Medical HepatologyDepartment of Infectious DiseasesDepartment of Traditional and Western Medical HepatologyDepartment of Traditional and Western Medical HepatologyDepartment of Traditional and Western Medical HepatologyDepartment of Traditional and Western Medical HepatologyDepartment of Traditional and Western Medical HepatologyDepartment of HepatologyDepartment of Traditional and Western Medical HepatologyDepartment of Infectious DiseasesObjective. To assess the geographic distribution of HCV genotypes, effectiveness, and safety of DAA treatment for HCV-infected patients in North and Northeast China. Methods. The geographic distribution of HCV genotypes was analyzed in 2162 patients recruited from April 2018 to February 2021. Sustained virologic response rates at 12 (SVR12) or 24 (SVR24) weeks posttreatment and safety were analyzed in 405 patients who completed DAA treatment according to patient baseline characteristics and treatment. Results. Four genotypes and six subtypes were identified as follows: 1b (1187, 54.90%), 2a (790, 36.54%), 3a/b (134, 6.20%), 6a/n (44, 2.04%), mixed genotypes (2a-6a or 2a-3a) (7, 0.32%). Overall, 99.01% patients achieved SVR12, while 98.43% achieved SVR24. All patients treated with elbasvir/grazoprevir (EBR/GZR), sofosbuvir/velpatasvir ± ribavirin (SOF/VEL ± RBV), and SOF/ledipasvir (LDV) achieved SVR12 or SVR24; 92.86% SVR12 and 95.83% SVR24 were observed in patients using SOF + RBV. SVR12 was higher in noncirrhosis versus compensated cirrhosis patients (100% vs. 97.09%, p=0.022). No severe drug-related adverse event was observed. Conclusions. Genotypes 1b and 2a were dominant subtypes in North and Northeast China. The approved drug regimens EBR/GZR and SOF/LDV for subtype 1b and SOF/VEL for nongenotype 1b are the optimal effective and safety profile.http://dx.doi.org/10.1155/2022/7395506 |
| spellingShingle | Wencong Li Jing Liang Jihong An Lingdi Liu Yihui Hou Lu Li Wen Zhao Luyao Cui Ningning Xue Zaid Al-Dhamin Tao Han Yuemin Nan Liaoyun Zhang Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study Canadian Journal of Gastroenterology and Hepatology |
| title | Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study |
| title_full | Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study |
| title_fullStr | Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study |
| title_full_unstemmed | Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study |
| title_short | Geographic Distribution of HCV Genotypes and Efficacy of Direct-Acting Antivirals in Chronic HCV-Infected Patients in North and Northeast China: A Real-World Multicenter Study |
| title_sort | geographic distribution of hcv genotypes and efficacy of direct acting antivirals in chronic hcv infected patients in north and northeast china a real world multicenter study |
| url | http://dx.doi.org/10.1155/2022/7395506 |
| work_keys_str_mv | AT wencongli geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT jingliang geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT jihongan geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT lingdiliu geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT yihuihou geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT luli geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT wenzhao geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT luyaocui geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT ningningxue geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT zaidaldhamin geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT taohan geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT yueminnan geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy AT liaoyunzhang geographicdistributionofhcvgenotypesandefficacyofdirectactingantiviralsinchronichcvinfectedpatientsinnorthandnortheastchinaarealworldmulticenterstudy |